ArticleBlood2015
The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.
Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.
- Factor XII-A New Therapeutic Target? A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Trial
- Systemic health impact of cancer-associated extracellular vesicles and particles.Nature reviews. Cancer · 2026Review
- Review
- Microfluidic Platforms for Modeling Cancer-Associated Thrombosis: Current Status and Future Directions.Research and practice in thrombosis and haemostasis · 2026Review
- A Snail Galactosed Glycosaminoglycan Inhibits Thrombosis without Affecting Hemostasis via Disrupting FIXa-FVIIIa Complex Generation.ACS central science · 2026Article
- Thrombosis-related gene signature predicts prostate cancer recurrence and immune therapy: insights from retrospective cohorts, bioinformatics, and experimental validation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Inorganic Polyphosphate and Human Diseases.Progress in molecular and subcellular biology · 2026Review
- Factor XII-driven coagulation traps bacterial infections.The Journal of experimental medicine · 2025Article
- Predicting Resistance and Survival of HCC Patients Post-HAIC: Based on Shapley Additive exPlanations and Machine Learning.Journal of hepatocellular carcinoma · 2025Article
- Enhanced proteomic profiling of human plasma-derived extracellular vesicles through charge-based fractionation to advance biomarker discovery potential.Journal of extracellular vesicles · 2024Article
- Article
- Inhibitors of Polyphosphate and Neutrophil Extracellular Traps.Seminars in thrombosis and hemostasis · 2024Review
- Inorganic Polyphosphate Is in the Surface ofPathogens (Basel, Switzerland) · 2024Article
- An Update on Polyphosphate In Vivo Activities.Biomolecules · 2024Review
- Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies.Current treatment options in oncology · 2024Review
- The pathogenesis of cancer-associated thrombosis.International journal of hematology · 2024Review
- Polyphosphate-loaded silk fibroin membrane as hemostatic agent in oral surgery: a pilot study.International journal of implant dentistry · 2023Article
- Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation.Blood advances · 2023Article
- Microparticle Phosphatidylserine Mediates Coagulation: Involvement in Tumor Progression and Metastasis.Cancers · 2023Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a leading cause of thrombosis. We identify a new procoagulant mechanism that contributes to thromboembolism in prostate cancer and allows for safe anticoagulation therapy development. Prostate cancer-mediated procoagulant activity was reduced in plasma in the absence of factor XII or its substrate of the intrinsic coagulation pathway factor XI. Prostate cancer cells and secreted prostasomes expose long chain polyphosphate on their surface that colocalized with active factor XII and initiated coagulation in a factor XII-dependent manner. Polyphosphate content correlated with the procoagulant activity of prostasomes. Inherited deficiency in factor XI or XII or high-molecular-weight kininogen, but not plasma kallikrein, protected mice from prostasome-induced lethal pulmonary embolism. Targeting polyphosphate or factor XII conferred resistance to prostate cancer-driven thrombosis in mice, without increasing bleeding. Inhibition of factor XII with recombinant 3F7 antibody reduced the increased prostasome-mediated procoagulant activity in patient plasma. The data illustrate a critical role for polyphosphate/factor XII-triggered coagulation in prostate cancer-associated thrombosis with implications for anticoagulation without therapy-associated bleeding in malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.